Huihui Chen

Hangzhou, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 15 publications

Timing and Patterns of Relapse-Related Events Following Adjuvant CDK4/6 Inhibitors Combined With Endocrine Therapy in Patients With HR-Positive, HER2-Negative Early Breast Cancer.

Timing and Patterns of Relapse-Related Events Following Adjuvant CDK4/6 Inhibitors Combined With Endocrine Therapy in Patients With HR-Positive, HER2-Negative Early Breast Cancer.

Journal: Cancer medicine

Published: February 27, 2026

Real-world outcomes of CDK4/6 inhibitors in combination with endocrine therapy as first-line treatment for HR-positive/HER2-negative advanced breast cancer: multicenter evidence from China.

Real-world outcomes of CDK4/6 inhibitors in combination with endocrine therapy as first-line treatment for HR-positive/HER2-negative advanced breast cancer: multicenter evidence from China.

Journal: BMC cancer

Published: January 23, 2026

Recent Advances in Antibody-Drug Conjugates and Immunotherapy Combinations for Treatment of Triple-Negative Breast Cancer.

Recent Advances in Antibody-Drug Conjugates and Immunotherapy Combinations for Treatment of Triple-Negative Breast Cancer.

Journal: Breast cancer (Dove Medical Press)

Published: September 29, 2025

Management of malignant breast phyllodes tumor with rib invasion during pregnancy: a rare case report and literature review.

Management of malignant breast phyllodes tumor with rib invasion during pregnancy: a rare case report and literature review.

Journal: Frontiers in oncology

Published: September 11, 2025

Efficacy, Safety, and Biomarkers of Neoadjuvant Dalpiciclib (CDK4/6 inhibitor) plus Aromatase Inhibitors in Operable HER2-Negative Luminal B Breast Cancer: A Prospective, Single-Center, Single-Arm, Phase II Trial (DANCER).

Efficacy, Safety, and Biomarkers of Neoadjuvant Dalpiciclib (CDK4/6 inhibitor) plus Aromatase Inhibitors in Operable HER2-Negative Luminal B Breast Cancer: A Prospective, Single-Center, Single-Arm, Phase II Trial (DANCER).

Journal: MedComm

Published: March 29, 2025

Investigation of Thrombocytopenia Associated with Trastuzumab Emtansine Treatment in Breast Cancer: A Retrospective Study in a Chinese Population.

Investigation of Thrombocytopenia Associated with Trastuzumab Emtansine Treatment in Breast Cancer: A Retrospective Study in a Chinese Population.

Journal: Breast cancer (Dove Medical Press)

Published: December 17, 2024

Predictive Significance of Systemic Immune-Inflammation Index in Patients with Breast Cancer: A Retrospective Cohort Study.

Predictive Significance of Systemic Immune-Inflammation Index in Patients with Breast Cancer: A Retrospective Cohort Study.

Journal: OncoTargets and therapy

Published: August 06, 2023

Cyclin-dependent kinase inhibition and its intersection with immunotherapy in breast cancer: more than CDK4/6 inhibition.

Cyclin-dependent kinase inhibition and its intersection with immunotherapy in breast cancer: more than CDK4/6 inhibition.

Journal: Expert opinion on investigational drugs

Published: July 05, 2022

Prognostic Models for Nonmetastatic Triple-Negative Breast Cancer Based on the Pretreatment Serum Tumor Markers with Machine Learning.

Prognostic Models for Nonmetastatic Triple-Negative Breast Cancer Based on the Pretreatment Serum Tumor Markers with Machine Learning.

Journal: Journal of oncology

Published: December 10, 2020

Glycoprotein hormone α-subunit promotes cell proliferation and tumorigenesis in breast cancer.

Glycoprotein hormone α-subunit promotes cell proliferation and tumorigenesis in breast cancer.

Journal: Oncology letters

Published: July 25, 2020

Molecular Mechanisms of PALB2 Function and Its Role in Breast Cancer Management.

Molecular Mechanisms of PALB2 Function and Its Role in Breast Cancer Management.

Journal: Frontiers in oncology

Published: December 01, 2019

High expression of UNC5B enhances tumor proliferation, increases metastasis, and worsens prognosis in breast cancer.

High expression of UNC5B enhances tumor proliferation, increases metastasis, and worsens prognosis in breast cancer.

Journal: Aging

Published: October 13, 2019

Showing 1-12 of 15

Last Updated: 09/26/2026